Luye Pharmaceuticals (02186): Innovative drug Ruoxinlin® approved in China for new indications to treat generalized anxiety disorder

Zhitongcaijing · 1d ago

Zhitong Finance App News, Luye Pharmaceutical (02186) issued an announcement. Ruoxinlin® (torudivenlafaxine hydrochloride sustained-release tablets), a Class 1 innovative drug independently developed by the Group, has been approved by the State Drug Administration for the treatment of generalized anxiety disorder. According to the company's knowledge, this product is the first innovative anti-anxiety chemical drug developed independently in China and has independent intellectual property rights, marking a major breakthrough in the field of treatment in China's original innovative drug.

Ruoxinlin ® was first approved for marketing in China in November 2022 to treat depression. The generalized anxiety disorder indication approved this time is the second indication obtained by this product in China. Ruoxinlin ® is the first and currently only serotonin (5-HT), norepinephrine (NE), and dopamine (DA) triple reuptake inhibitor (SNDRI) in China. Clinical studies have confirmed that the product can quickly and comprehensively improve anxiety symptoms, has a high efficiency and relief rate, can significantly promote the improvement of patients' overall condition and recovery of social function, and has good overall safety and tolerability, bringing new differentiated treatment options to patients with widespread anxiety disorder.